Biogen (NASDAQ:BIIB) has had a mixed run in recent times. Shares hit a fresh 12-month low and several analysts have downgraded the stock due to concerns over pipeline setbacks and slowing sales of its drug Leqembi. However, indications suggest oversold conditions for Biogen's stocks, which could pique investors' interest. Prominent players, such as Oddo BHF Asset Management, Inspire Trust Co, and Geode Capital, have increased their position in Biogen. Moreover, Biogen's recent performance records increases in revenues, surpassing estimates, and the company has raised its profit guidance due to gains in Alzheimer's drug Leqembi. Collaborations and acquisitions reflecting the company's growth strategy, such as the partnership with Beckman Coulter and Fujirebio, and the acquisition of Human Immunology Biosciences, have bolstered its late-stage pipeline and expanded its immunology portfolio. Beside all these
innovative developments, the approval of the Alzheimer's treatment
Leqembi, across various nations including Great Britain, Israel, China, and South Korea shows the growing traction of its products. Any negative sentiment seems to revolve around a perceived lackluster performance of its healthcare stocks and a substantial decline in stock value over the last three years.
Biogen BIIB News Analytics from Wed, 31 Jan 2024 08:00:00 GMT to Sat, 14 Dec 2024 16:06:27 GMT -
Rating -3
- Innovation 8
- Information 7
- Rumor 9
